NVDA
NVIDIA
-- 126.630 TSLA
Tesla
-- 302.800 SMCI
Super Micro Computer
-- 45.540 PLTR
Palantir
-- 87.840 BABA
Alibaba
-- 134.010 
NEWS
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug than daily oral doses. Participants reported higher satisfaction and a strong preference for the SC route. The FDA End-of-Phase 2 interaction is expected by year-end, aiming for a Phase 3 pivotal study. Adverse events were mostly mild, with no serious adverse events reported.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment